There is little doubt that for most pet owners, Fido is part of the family—and may represent a good way to diversify pharmacy topline revenue. Popular retailer PetSmart launched an online pet pharmacy in 2017, and this week, Walmart got on board with their own launch of an online pet pharmacy. It also announced a plan to expand its existing roster of store-based pet vet clinics from 21 to 100 over the next year. The market is ripe—especially among certain demographics—who want options for buying their pet meds. Despite cautions around purchasing Fido’s medications online, as shared by this New Hampshire-based vet clinic, pulling people into the pharmacy for pet meds won’t be easy, but it’s been a boon for this independent. If you are looking to add pet care to your lineup, check out these ideas for stepping into the market.
This week, Merck announced it was responding to an uptick in demand for the measles vaccine during the largest outbreak in a quarter century. From January to April 26 this year, the CDC reports 704 cases have been confirmed in 22 states. Offshore, a cruise ship has been quarantined after a confirmed case of measles was reported, with broad exposure among passengers feared. A 2015 New York bill to drop religious exemptions for vaccinations is stalled despite the area being one of the heaviest hit by the outbreak.
“Often staying successful is about learning and changing rather than sticking to the tried-and-true.” —Dane Holmes, Head of Human Capital Management, Goldman Sachs
This week, AARP and McDonald’s announced a program to help fill a quarter of a million seasonal jobs and a pilot program designed to match low-income seniors with jobs. When Goldman Sachs faced a recruiting crisis, it took two key steps to make sure it was reaching the best talent available: It widened the funnel to capture a broader range of applicants and identified the key competencies required to succeed at the firm, then stuck to structured questions to get at those competencies.
A subcommittee of the House Energy and Commerce Committee heard testimony earlier this month on the human toll of rising insulin costs as a case study to better understand the impact on patients on prescription pricing overall. According to Rep. Brett Guthrie (R-KY 2nd District), “The prescription drug supply chain is complex, and it lacks transparency. There is limited public information around drug prices due to a lack of transparency around rebates and other price concessions.” The Kaiser Family Foundation recently reported that total Medicare Part D spending on insulin increased by 840% between 2007 and 2017, with no generics available and Eli Lilly, Novo Nordisk, and Sanofi dominating the market. In Minnesota, Attorney General Lori Swanson sued the three. While common wisdom (and massive advertising dollars spent by the Big Pharma lobby) justify high prices as attributable to the cost of R&D, rising insulin costs—which have been averaging 10 percent annually—may go a long way toward putting that argument to bed.
In the midst of an opioid crisis—and where substance abuse is in the headlines nearly every day—treating patients’ pain is a considerable challenge. In the case of cancer patients, for example, opioids remain the go-to, but there are additional approaches available, including drug therapies that change the mind’s perception of pain or those that block the pain signal from traveling to the brain. Researchers are also exploring gene therapies and approaches that juice the feel-good chemicals in the body.
In a close vote, an advisory panel has recommended that practitioners co-prescribe naloxone with opioid prescriptions, and the recommendation is currently under review by the FDA. Health and Human Services has echoed the recommendation, providing guidance to prescribe naloxone for individuals at risk of opioid overdose, “including, but not limited to: individuals who are on relatively high doses of opioids, take other medications which enhance opioid complications or have underlying health conditions.” Proponents have suggested the recommendation could promote a healthy dialogue between providers and patients. However, detractors like Mary Ellen McCann, associate professor of anesthesia at Harvard Medical School, think the measure is too expensive—and potentially ineffective.
After the acquisition of PillPack last year, Amazon has flown fairly low on the radar when it comes to its potential pharmacy business. Last week, however, the firm announced the hire of Nader Kabbani to run its fledgling pharmacy venture. Will the same Amazon executive who led Kindle to disrupt traditional book sales be the right fit for the new role? Possibly—and he’s not alone.
Even as a widespread outbreak of measles worries health officials in the Pacific Northwest, Facebook is under fire for spreading anti-vax messages via group recommendations. The algorithms that power websites where Americans get often inaccurate health-related information from, says Rep. Adam Schiff (D-CA), “are not designed to distinguish quality information from misinformation or misleading information, and the consequences of that are particularly troubling for public health issues.” The Wall Street Journal is reporting that another social platform, Pinterest, has stopped returning search results for “vaccination” in an effort to curb misinformation. Studies have even connected immunization with better heart health, which makes February a great time to talk with patients about vaccines like Tdap. Besides being a public health threat, there’s no doubt that immunizations create opportunities for both revenue—but what can pharmacists do to promote them, especially among the unscientifically inclined? Here’s a place to start: Check out this audio discussion with some of the misinformation surrounding vaccination, and feel free to share the link with your patients via email or across your social media feeds.
Here are a few other stories that might be of interest: